CEP 9722

Drug Profile

CEP 9722

Alternative Names: CEP-9722; CK-102

Latest Information Update: 20 Mar 2017

Price : $50

At a glance

  • Originator Cephalon
  • Developer Cephalon; Checkpoint Therapeutics
  • Class Antineoplastics; Carbazoles; Piperazines; Pyrrolidinones; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • No development reported Mantle-cell lymphoma
  • Discontinued Non-small cell lung cancer

Most Recent Events

  • 16 Mar 2017 Phase-I development is ongoing for Solid tumours in Bengium, France, USA and United Kingdom
  • 16 Mar 2017 Checkpoint plans a phase Ib trial for Solid tumours
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Mantle-cell-lymphoma(Combination therapy, Late-stage disease) in Belgium (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top